Preview

Russian Journal of Cardiology

Advanced search

Implemented models and perspectives of managing lipid metabolism disorders. Concept of rare lipid disease centers

https://doi.org/10.15829/1560-4071-2021-4538

Abstract

Despite the advances in lipidology over the past decade, the control of dyslipidemia at the population level in Russia, as in a number of European countries, remains unsatisfactory. The need for novel organizational approaches to solving the problem at the regional and federal levels is obvious. This publication provides an overview of the implemented projects and the successful practical experience of lipid centers in Russia, as well as the prospects for the development of novel models that will optimize the care provision for patients with lipid metabolism disorders at the population level.

About the Authors

A. S. Alieva
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests:

No



O. V. Reutova
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests:

No



E. I. Pavlyuk
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests:

No



D. V. Duplyakov
Samara Regional Clinical Cardiology Dispensary; Samara State Medical University
Russian Federation

Samara.


Competing Interests:

No



A. V. Khripun
Rostov Regional Clinical Hospital
Russian Federation

Rostov-on-Don.


Competing Interests:

No



I. P. Efimova
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests:

No



Yu. A. Guryanova
B.A. Korolev Specialized Cardiac Surgery Clinical Hospital
Russian Federation

Nizhny Novgorod.


Competing Interests:

No



E. S. Timoshchenko
City Cardiology Dispensary
Russian Federation

Nizhny Novgorod.


Competing Interests:

No



A. A. Nekrasov
City Cardiology Dispensary
Russian Federation

Nizhny Novgorod.


Competing Interests:

No



A. M. Namitokov
S.V. Ochapovsky Regional Clinical Hospital № 1; Kuban State Medical University
Russian Federation

Krasnodar.


Competing Interests:

No



V. K. Zafiraki
Regional Clinical Hospital № 2; Kuban State Medical University
Russian Federation

Krasnodar.


Competing Interests:

No



E. D. Kosmacheva
S.V. Ochapovsky Regional Clinical Hospital № 1; Regional Clinical Hospital № 2
Russian Federation

Krasnodar.


Competing Interests:

No



V. A. Korneva
Petrozavodsk State University
Russian Federation

Petrozavodsk.


Competing Interests:

No



N. N. Vezikova
Petrozavodsk State University
Russian Federation

Petrozavodsk.


Competing Interests:

No



I. S. Skopets
Petrozavodsk State University
Russian Federation

Petrozavodsk.


Competing Interests:

No



N. E. Zvartau
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests:

No



E. V. Shlyakhto
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests:

No



References

1. Ray KK, Molemans B, Schoonen WM, et al., 2020. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. European Journal of Preventive Cardiology. 2020;zwaa047, doi:10.1093/eurjpc/zwaa047.

2. Yezhov MV, Bliznyuk SA, Tmoyan NA, et al. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Russian Journal of Cardiology. 2019;24(5):7-13. (In Russ.) doi:10.15829/1560-4071-2019-5-7-13.

3. Besseling J, Reitsma JB, Gaudet D, et al. Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. Eur Heart J. 2017;38(8):565-73. doi:10.1093/eurheartj/ehw135.

4. Averna M, Cefalu AB, Casula M, et al. LIPIGEN Group. Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atheroscler Suppl. 2017;29:11-6. doi:10.1016/j.atherosclerosissup.2017.07.001.

5. EAS Familial Hypercholesterolaemia Studies Collaboration; Vallejo-Vaz AJ, De Marco M, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries — The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234-55. doi:10.1016/j.atherosclerosis.2018.08.051.

6. Goldberg AC, Hopkins PN, Toth PP, et al. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adultpatients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1-8. doi:10.1016/j.jacl.2011.04.003.


Supplementary files

Review

For citations:


Alieva A.S., Reutova O.V., Pavlyuk E.I., Duplyakov D.V., Khripun A.V., Efimova I.P., Guryanova Yu.A., Timoshchenko E.S., Nekrasov A.A., Namitokov A.M., Zafiraki V.K., Kosmacheva E.D., Korneva V.A., Vezikova N.N., Skopets I.S., Zvartau N.E., Shlyakhto E.V. Implemented models and perspectives of managing lipid metabolism disorders. Concept of rare lipid disease centers. Russian Journal of Cardiology. 2021;26(6):4538. https://doi.org/10.15829/1560-4071-2021-4538

Views: 1099


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)